A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving ...

A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving acute myeloid leukemia (AML), an aggressive blood cancer affecting the bone ...

CRISPR Therapeutics (NasdaqGM:CRSP) reports significant progress in the commercial rollout of Casgevy, its approved gene editing therapy for sickle cell disease. Patient initiations for Casgevy have ...

One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand treatment to others.

Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple ...

昨年8月、KJ・マルドゥーンは致命的となりうる遺伝子疾患をもって生まれた。それからわずか6カ月後、彼は自分だけのために設計されたCRISPR治療を受けた。 マルドゥーンは、血液中に危険な量のアンモニアが蓄積されるCPS1欠損症という希少疾患を患っている ...

CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for 2026. Click here to read now.

CRISPR Therapeutics AG CRSP on Friday reported its fourth-quarter and full-year 2025 financial results, highlighting ...

CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...

A sales partner offered a ray of hope that this company couldn't for itself.

CRISPR Therapeutics is commercially validated with CASGEVY but remains financially unproven and operates at a loss. Click to read this CRSP stock update.